The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
SMC proteins can reverse direction, reshaping DNA and solving key scientific debates. This discovery could impact research on ...
What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...
The FDA rejected the company’s initial NDA in 2021, citing the lack of an adequate trial to demonstrate efficacy.
US clinical-stage drug developer Stealth BioTherapeutics announced that the US Food and Drug Administration (FDA) has ...
FDA delays Stealth BioTherapeutics' elamipretide decision to April 29; Valneva's Ixchiq succeeds in child safety trial; TargetRx raises $50M; Ab&B Bio-Tech files for HKEX IPO ...
An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...
Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome ...
A senior at Academy of Notre Dame, Katie Barth is a Global Citizen Scholar candidate, a Blue and Gold Key Society member, and active member of Mock Trial and Model UN clubs and started Academy of ...